Coherus BioSciences Q2 2024 Adj. EPS $(0.14) Beats $(0.29) Estimate, Sales $65.000M Beat $61.366M Estimate
Portfolio Pulse from Benzinga Newsdesk
Coherus BioSciences (NASDAQ:CHRS) reported better-than-expected Q2 2024 results with an adjusted EPS of $(0.14) beating the $(0.29) estimate and sales of $65 million surpassing the $61.366 million estimate. This represents a 10.70% increase over the same period last year.
August 08, 2024 | 8:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences reported Q2 2024 adjusted EPS of $(0.14), beating the $(0.29) estimate, and sales of $65 million, surpassing the $61.366 million estimate. This positive earnings surprise and revenue growth of 10.70% year-over-year is likely to boost investor confidence in the short term.
The company's better-than-expected earnings and revenue growth indicate strong performance, which is likely to positively impact the stock price in the short term. The significant beat on EPS and sales figures will likely boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100